原发性醛固酮患者心血管与肾脏的预后及影响因素

吴瑾 卉1, 郭子 墨1, 俞 芳2
1.华北理工大学研究生院；2.唐山市工人医院内分泌科 河北 唐山 063000

摘要

目的：原发性醛固酮增多症（PA）是最常见的内分泌高血压类型。大量实验和临床证据已证实，长期暴露于过量醛固酮会增加 PA 患者发生心脑血管事件和靶器官损害（TOD）的风险。目前的证据显示，从长远来看，手术和药物治疗都有益于心脑血管结局和死亡率，经过治疗后大部分患者都可获得临床和/或生化缓解。以外，仍有一部分患者遗留持续的高血压，本文也将就 PA 患者预后的影响因素进行讨论。

关键词

原发性醛固酮增多症 预后 影响因素

参考

[1]Xu Z, Yang J, Hu J, Song Y, He W, Luo T, Cheng Q, Ma L, Luo R, Fuller PJ, Cai J, Li Q, Yang S; Chongqing Primary Aldosteronism Study (CONPASS) Group. Primary Aldosteronism in Patients in China With Recently Detected Hypertension. J Am Coll Cardiol. 2020 Apr 28;75(16):1913-1922. [2]Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50. [3]Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002 Jul;40(1):23-7. [4]Cesari M, Letizia C, Angeli P, Sciomer S, Rosi S, Rossi GP. Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism: A Tissue Doppler Study. Circ Cardiovasc Imaging. 2016 Jun;9(6):e004815. [5]Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013 Dec;98(12):4826-33. doi: 10.1210/jc.2013-2805. Epub 2013 Sep 20. PMID: 24057288. [6]Monticone S, Sconfienza E, D'Ascenzo F, Buffolo F, Satoh F, Sechi LA, Veglio F, Mulatero P. Renal damage in primary aldosteronism: a systematic review and meta-analysis. J Hypertens. 2020 Jan;38(1):3-12. [7]Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F; PAPY Study Participants. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006 Aug;48(2):232-8. [8]Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006 Jun 14;295(22):2638-45. [9]Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens. 2010 Dec;23(12):1253-60. [10]Catena C, Colussi G, Sechi LA. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era. Eur J Endocrinol. 2012 Dec 10;168(1):C1-5. [11]Rossi GP, Maiolino G, Flego A, Belfiore A, Bernini G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Muiesan ML,Mannelli M, Negro A, Palumbo G, Parenti G, Rossi E, Mantero F; PAPY Study Investigators. Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. Hypertension. 2018 Apr;71(4):585-591. [12]Wu VC, Chueh SJ, Chen L, Chang CH, Hu YH, Lin YH, Wu KD, Yang WS; TAIPAI Study Group. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J Hypertens. 2017 Aug;35(8):1698-1708. [13]Wu VC, Wang SM, Chang CH, Hu YH, Lin LY, Lin YH, Chueh SC, Chen L, Wu KD. Long term outcome of Aldosteronism after target treatments. Sci Rep. 2016 Sep 2;6:32103. [14]Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018 Jan;6(1):51-59. [15]Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007 Nov;50(5):911-8. [16]Cicala M, Cesari M, Patalano A, Iacobone M, Mariniello B, Mantero F . Treatment of primary aldosteronism: short and middle-term effects of medical and surgical therapy in primary hyperaldosteronism: experience of 45 cases. J Hypertens 2010; 28(e-Supplement A):305. [17]Sechi LA, Catena C. The dual role of the kidney in primary aldosteronism: key determinant in rescue from volume expansion and persistence of hypertension. Am J Kidney Dis. 2009 Oct;54(4):594-7. [18]Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WF Jr, Gomez-Sanchez CE, Funder JW, Reincke M; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699. [19]Picado O, Whitfield BW, Khan ZF, Jeraq M, Farrá JC, Lew JI. Long-term outcome success after operative treatment for primary aldosteronism. Surgery. 2021 Mar;169(3):528-532. [20]Zarnegar R, Young WF Jr, Lee J, Sweet MP, Kebebew E, Farley DR, Thompson GB, Grant CS, Clark OH, Duh QY. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg. 2008 Mar;247(3):511-8. [21]Clemente-Gutiérrez U, Pérez-Soto RH, Hernández-Acevedo JD, Iñiguez-Ariza NM, Casanueva-Pérez E, Pantoja-Millán JP, Sierra-Salazar M, Herrera MF, Velázquez-Fernández D. Endocrine hypertension secondary to adrenal tumors: clinical course and predictive factors of clinical remission. Langenbecks Arch Surg. 2021 Sep;406(6):2027-2035. [22]Onohara T, Takagi T, Yoshida K, Iizuka J, Okumi M, Kondo T, Ishida H, Tanabe K. Assessment of postoperative renal function after adrenalectomy in patients with primary aldosteronism. Int J Urol. 2019 Feb;26(2):229-233. [23]Utsumi T, Kawamura K, Imamoto T, Kamiya N, Komiya A, Suzuki S, Nagano H, Tanaka T, Nihei N, Naya Y, Suzuki H, Tatsuno I, Ichikawa T. High predictive accuracy of Aldosteronoma Resolution Score in Japanese patients with aldosterone-producing adenoma. Surgery. 2012 Mar;151(3):437-43. [24]He XQ, Yang S, Wu JL, Wang DL, Ren W, Cheng QF, Zhen QN, Cao YD, Li QF, Zhou B. [A Fisher discriminant model to predict the outcome of postoperative blood pressure in primary aldosteronism]. Zhonghua Yi Xue Za Zhi. 2016 Nov 15;96(42):3379-3383. Chinese. [25]Burrello J, Burrello A, Stowasser M, Nishikawa T, Quinkler M, Prejbisz A, Lenders JWM, Satoh F, Mulatero P, Reincke M, Williams TA. The Primary Aldosteronism Surgical Outcome Score for the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Ann Surg. 2020 Dec;272(6):1125-1132. [26]Velema M, Dekkers T, Hermus A, Timmers H, Lenders J, Groenewoud H, Schultze Kool L, Langenhuijsen J, Prejbisz A, van der Wilt GJ, Deinum J; SPARTACUS investigators. Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment. J Clin Endocrinol Metab. 2018 Jan 1;103(1):16-24. 第一作者简介：姓名：吴瑾卉，性别：女，民族：汉族，出生年月：1998 年 12 月，籍贯：河北邢台，学历：硕士研究生，研究方向：原发性醛固酮增多症